Eli Lilly And Co (LLY) Holdings Lifted by Grimes & Company Inc.

Grimes & Company Inc. boosted its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 4.2% during the 1st quarter, HoldingsChannel reports. The fund owned 4,399 shares of the company’s stock after purchasing an additional 177 shares during the period. Grimes & Company Inc.’s holdings in Eli Lilly And Co were worth $571,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of LLY. Athena Capital Advisors LLC bought a new position in Eli Lilly And Co during the fourth quarter worth about $26,000. Wakefield Asset Management LLLP bought a new position in Eli Lilly And Co during the fourth quarter worth about $27,000. Larson Financial Group LLC bought a new position in Eli Lilly And Co during the fourth quarter worth about $29,000. Trust Department MB Financial Bank N A lifted its holdings in Eli Lilly And Co by 54.7% during the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after acquiring an additional 82 shares in the last quarter. Finally, Acima Private Wealth LLC bought a new position in Eli Lilly And Co during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 84.49% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 195,000 shares of the company’s stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $124.19, for a total transaction of $24,217,050.00. Following the sale, the insider now owns 117,425,304 shares in the company, valued at $14,583,048,503.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Christi Shaw sold 7,577 shares of the company’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $117.14, for a total value of $887,569.78. Following the sale, the senior vice president now owns 500 shares in the company, valued at approximately $58,570. The disclosure for this sale can be found here. Insiders have sold 640,959 shares of company stock worth $81,539,352 in the last quarter. 0.11% of the stock is currently owned by corporate insiders.

Several research analysts have weighed in on the company. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday. TheStreet lowered Eli Lilly And Co from a “b+” rating to a “c+” rating in a report on Thursday, May 9th. BMO Capital Markets boosted their price target on Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Cantor Fitzgerald restated a “buy” rating and issued a $143.00 price target on shares of Eli Lilly And Co in a report on Tuesday, April 30th. Finally, Edward Jones upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price target on the stock in a report on Tuesday, April 23rd. Eleven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $118.15.

Shares of Eli Lilly And Co stock opened at $116.58 on Wednesday. The stock has a market capitalization of $112.63 billion, a PE ratio of 21.01, a PEG ratio of 2.06 and a beta of 0.27. Eli Lilly And Co has a one year low of $81.61 and a one year high of $132.13. The company has a debt-to-equity ratio of 5.50, a quick ratio of 0.85 and a current ratio of 1.12.

Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.12 billion. During the same quarter in the prior year, the company posted $1.31 earnings per share. Eli Lilly And Co’s revenue was up 2.6% on a year-over-year basis. Analysts predict that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, June 10th. Investors of record on Friday, May 17th will be issued a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $2.58 annualized dividend and a yield of 2.21%. Eli Lilly And Co’s payout ratio is presently 46.49%.

TRADEMARK VIOLATION WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2019/05/22/eli-lilly-and-co-lly-holdings-lifted-by-grimes-company-inc.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: How does the Federal Reserve determine interest rates?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.